Odyssey's OD-001 Clears Phase 2a Primary Endpoint in Ulcerative Colitis

summarizeSummary

Odyssey reported completed Phase 2a induction data showing OD-001 met its primary endpoint in ulcerative colitis, with 27% clinical remission at 20 mg BID and a clean safety profile. The company is advancing into Phase 2b monotherapy and a vedolizumab combination trial, with topline data expected in H2 2027.

check_boxKey Events · Product Development and Regulatory · ODTX

• OD-001 Meets Phase 2a Primary Endpoint

  Across 56 efficacy-evaluable patients, mean modified Mayo score fell 2.4 points at Week 12 (p<0.001).

• 27% Clinical Remission at 20 mg BID

  At 20 mg BID (n=41), clinical response reached 61% and symptomatic remission 49%, versus 20%/40%/27% at 10 mg BID (n=15).

• Activity Holds in Hard-to-Treat Patients

  Remission reached 23% in advanced therapy-experienced patients and 16% in those with severe endoscopic disease (MES=3).

• Clean Safety and Tolerability Profile

  No serious adverse events, serious infections, or treatment-related discontinuations occurred; three drug-related events at 20 mg BID (two fevers, one headache).

auto_awesomeAnalysis · ODTX · Life Sciences

The completed 56-patient induction analysis confirms OD-001 met its primary endpoint, with a 2.4-point reduction in modified Mayo score (p<0.001) and 27% clinical remission at 20 mg BID against a 10% historic placebo benchmark. Equally important, remission held at 23% in patients who had already failed advanced therapies and reached 16% in the most severe endoscopic disease—the population where existing oral drugs fade. A clean safety profile (no SAEs, no serious infections, no discontinuations) supports positioning OD-001 as a combination backbone. Next comes a placebo-controlled Phase 2b and a vedolizumab combination trial, with topline induction data expected in H2 2027; those randomized readouts, not this open-label data, will determine whether the program holds its valuation.